English Intern
Institut für Pharmazie und Lebensmittelchemie

Publikationen

Originalarbeiten
  • Moro O, Lameh J, Högger P, Sadée W.
    Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling.
    J Biol Chem 1993; 268:22273-22276.
  • Högger P, Rohdewald P.
    Pharmacokinetics of bromfenac in healthy subjects after single oral administration of three different doses.
    Arzneimittelforschung 1993; 43:1114-1118.
  • Högger P, Rohdewald P.
    Binding kinetics of fluticasone propionate to the human glucocorticoid receptor.
    Steroids 1994; 59:597-602.
  • Högger P, Shockley MS, Lameh J, Sadée W.
    Activating and inactivating mutations in N- and C-terminal i3 loop junctions muscarinic acetylcholine Hm1 receptors.
    J Biol Chem 1995; 270:7405-7410.
  • Rohdewald P, Bonsmann U, Högger P.
    Die Bindung inhalativer Glukokortikoide an menschliches Lungengewebe in vitro
    In Neue Aspekte der inhalativen Glukokortikoid-Therapie des Asthma bronchiale;
    W. Leupold and D. Nolte, Ed.; Dustri-Verlag Dr. Karl Feistle: München-Deisenhofen, 1995; pp 14-27.
  • Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P.
    Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo.
    Eur Respir J 1997; 10:1496-1469.
  • Högger P, Erpenstein U, Rohdewald P, Sorg C.
    Biochemical characterization of a glucocorticoid-induced membrane protein (RM 3/1) on human monocytes and its application as model system for ranking glucocorticoid potency.
    Pharm Res 1998; 15:296-302.
  • Dreier J, Högger P, Sorg C.
    Rapid method for isolation of total RNA from eucaryotic cell lines and leucocytes.
    DNA Cell Biol 1998; 17:321-323.
  • Högger P, Dreier J, Droste A, Buck F, Sorg C.
    Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163).
    J Immunol 1998; 161:1883-1890.
  • Esmailpour N, Högger P, Rohdewald P.
    Binding kinetics of budesonide to the human glucocorticoid receptor.
    Eur J Pharm Sci 1998; 6:219-223.
  • Högger P, Rohdewald P.
    Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized cross-over study in healthy human volunteers.
    Int J Clin Pharm Ther 1999; 37:377-385.
  • Droste A, Sorg C, Högger P.
    Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family.
    Biochem Biophys Res Commun 1999; 256:110-113.
  • Van den Heuvel MM, Tensen CP, van As JA, Van den Berg TK, Fluitsma DM, Dijkstra CD, Döpp EA, Droste A, Van Galen FA, Högger P, Beelen RHJ.
    Regulation of the expression of the cysteine-rich scavenger receptor CD163 on human macrophages: cross-linking of CD163 induces signalling and activation. J Leukoc Biol 1999; 66:858-866.
  • Kassack MU, Högger P, Gschwend DA, Kameyama K, Haga T, Sadée W.
    Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors.
    AAPS PharmSci. 2000; 2:E2.
  • Esmailpour N, Högger P, Rohdewald P.
    Tissue binding of glucocorticoids to human nasal tissue in vitro.
    Int Arch Allergy Immunol 2000; 122:151-154.
  • Högger P.
    Adverse effects of opioid analgesic treatment are correlated with a significant elevation in plasma epinephrine.
    Eur J Clin Pharmacol 2000; 56:463-468.
  • Sulahian TH, Högger P, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Guyre PM.
    Human monocytes express CD163 which is upregulated by IL-10 and identical to p155.
    Cytokine 2000; 12:1312-1321.
  • Högger P.
    Comparison of the tissue affinity of glucocorticoids to human lung, nasal and skin tissue in vitro.
    Arzneimittelforschung 2001; 51:825-831.
  • Högger P, Sorg C.
    Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation.
    Biochem Biophys Res Commun 2001; 288:841-843.
  • Matsushita N, Kashiwagi M, Wait R, Nagayoshi R, Nakamura M, Matsuda T, Högger P, Guyre PM, Nagase H, Matsuyama T.
    Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3.
    Clin Exp Immunol 2002; 130:156-161.
  • Grimm T, Schäfer A, Högger P.
    Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (Pycnogenol).
    Free Radic Biol Med 2004; 36:811-822.
  • Valotis A, Neukam K, Elert O, Högger P.
    Human receptor kinetics, tissue binding affinity and stability of mometasone furoate.
    J Pharm Sci 2004; 93:1337-1350.
  • Valotis A, Högger P.
    Significant receptor affinities of metabolites and a degradation product of mometasone furoate.
    Respir Res 2004; 5:7.
  • Afify S, Rapp UR, Högger P.
    Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
    J Chromatogr B Analyt Technol Biomed Life Sci 2004; 809:99-103.
  • Timmermann M, Buck F, Sorg C, Högger P.
    Interaction of soluble CD163 with activated T-lymphocytes involves its association with nonmuscle myosin heavy chain – A.
    Immunol Cell Biol 2004; 82:479-487.
  • Timmermann M, Högger P.
    Oxidative stress and 8-iso-prostaglandin F2a induce ectodomain shedding of CD163 and release of tumor necrosis factor a from human monocytes.
    Free Radic Biol Med 2005; 39:98-107.
  • Freiwald M, Valotis A, Kirschbaum A, McClellan M, Mürdter T, Fritz P, Friedel G, Thomas M, Högger P.
    Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model.
    Respir Res 2005; 6:21.
  • Schäfer A, Chovanová Z, Muchová J, Sumegová K, Liptákova A, Ďuračková Z, Högger P.
    Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol).
    Biomed Pharmacother 2006; 60:5-9.
  • Grimm T, Chovanová Z, Muchová J, Sumegová K, Liptákova A, Ďuračková Z, Högger P.
    Inhibition of NF-kB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol).
    J Inflamm 2006; 3:1.
  • Grimm T, Skrabala R, Chovanová Z, Muchová J, Sumegová K, Liptákova A, Ďuračková Z, Högger P.
    Single and multiple dose pharmacokinetics of maritime pine bark extract (Pycnogenol) after oral administration to healthy volunteers.
    BMC Clin Pharmacol 2006; 6:4.
  • Schäfer A, Högger P.
    Oligomeric procyanidins of French maritime pine bark extract (Pycnogenol®) effectively inhibit a-glucosidase.
    Diabetes Res Clin Pract 2007; 77: 41-46.
  • Attia M, Timmermann M, Högger P, Herdeis C.
    Design, synthesis and biological activity of azasugar-based CD163 ectodomain shedding inhibitors.
    Eur J Org Chem 2007; 22: 3669-3675.
  • Valotis A, Högger P.
    Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.
    Respir Res 2007; 8: 54.
  • Trammer B, Amann A, Haltner-Ukomadu E, Tillmanns S, Keller M, Högger P.
    Comparative permeability and diffusion kinetics of cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood ex vivo.
    Eur J Pharm Biopharm 2008; 70: 758-764.
  • Baumann D, Bachert C, Högger P.
    Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo.
    Clin Exp Allergy 2009; 39: 1540-1550.
  • Basar S, Uhlenhut K, Högger P, Schöne F, Westendorf J.
    Analgesic and anti-inflammatory activity of Morinda citrifolia L. (Noni) fruit.
    Phytother Res 2010; 24: 38-42.
  • Kurlbaum M, Högger P.
    Plasma protein binding of polyphenols from maritime pine bark extract (USP).
    J Pharm Biomed Anal 2011; 54: 127-132.
  • Hobl EL, Mader RM, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Kalipciyan M, Jilma B.
    The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Clin Exp Rheumatol 2011; 29: 963-969
  • Baumann D, Bachert C, Högger P.
    Development of a novel model for comparative evaluation of intranasal pharmacokinetics and effects of anti-allergic nasal sprays.
    Eur J Pharm Biopharm 2012; 80: 156-163.
  • Gnadt M, Trammer B, Freiwald M, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, Friedel G, Högger P.
    Methacholine delays pulmonary absorption of inhaled b2-agonists due to competition for organic cation / carnitine transporters.
    Pulm Pharmacol Ther 2012; 25: 124-134.
  • Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, Mader R.
    A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.
    Clin Exp Rheumatol 2012; 30: 156-163.
  • Hobl EL, Mader R, Jilma B, Duhm B, Mustak M, Bröll H, Högger P, Erlacher L.
    A randomized double-blind, parallel, single site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis.
    Clin Ther 2012; 34: 1195-1203.
  • Uhlenhut K, Högger P.
    Pitfalls and limitations in using 4,5-diaminofluorescein (DAF-2) for evaluating the influence of polyphenols on nitric oxide release from endothelial cells.
    Free Radic Biol Med 2012; 52: 2266-2275.
  • Ahmed A, Prime D, Burnell PKP, Högger P.
    Development of an in vitro model to assess deposition of aerosol particles in a representative replica of the rat’s respiratory tract.
    J Aerosol Med Pulm Drug Deliv 2012; 25: 169-178.
  • Uhlenhut K, Högger P.
    Facilitated cellular uptake and suppression of inducible nitric oxide synthase (iNOS) by a metabolite of maritime pine bark extract (Pycnogenol).
    Free Radic Biol Med 2012; 53: 305-313.
  • Enseleit F, Sudano I, Périat D, Winnik S, Wolfrum M, Flammer AJ, Fröhlich GM, Kaiser P, Hirt A, Haile SR, Krasniqi N, Matter CM, Uhlenhut K, Högger P, Neidhart M, Lüscher TF, Ruschitzka F, Noll G.
    Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease – a double-blind, randomized, placebo-controlled, crossover study.
    Eur Heart J 2012; 33: 1589-97.
  • Gnadt M, Trammer B, Kardziev B, Bayliss MK, Edwards CD, Schmidt M, Högger P.
    Comparison of the bronchodilating effects of inhaled2-agonists after methacholine challenge in a human lung reperfusion model.
    Eur J Pharm Biopharm 2012; 81: 617-626.
  • Gnadt M, Kardziev B, Schmidt M, Högger P.
    Surfactant protein A (SP-A) and angiotensin converting enzyme (ACE) as early biomarkers for pulmonary edema formation in ventilated human lung lobes.
    Lung 2012; 190: 431-440.
  • Kurlbaum M, Mülek M, Högger P.
    Facilitated uptake of a bioactive metabolite of maritime pine bark extract (Pycnogenol) into human erythrocytes.
    PLoS One 2013; 8: e63197.
  • Germershaus O, Schultz I, Lühmann T, Beck-Broichsitter M, Högger P, Meinel L.
    Insulin-like growth factor-I aerosol formulation for pulmonary delivery.
    Eur J Pharm Biopharm 2013; 85: 61-68.
  • Zhang N, Van Crombruggen K, Holtappels G, Lan F, Katotomichelakis M, Zhang L, Högger P, Bachert C.
    Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human mucosal tissue ex-vivo.
    PLoS One 2014; 9: e93754.
  • Trammer B, Kardziev B, Schmidt M, Högger P.
    Analysis of fenoterol and ipratropium transfer from human lung tissue into human plasma using a dynamic dialysis model.
    BJPR 2014; 4: 1287-1299.
  • Mülek M, Högger P.
    Highly sensitive analysis of polyphenols and their metabolites in human blood cells using dispersive SPE extraction and LC-MS/MS.
    Anal Bioanal Chem 2015; 407: 1885-1899.
  • Schultz I, Vollmers F, Lühmann T, Rybak JC, Wittmann R, Stank K, Steckel H, Kardziev B, Schmidt M, Högger P, Meinel L.
    Pulmonary insulin-like growth factor I delivery from trehalose and silk-fibroin microparticles.
    ACS Biomater Sci Eng 2015; 1: 119-129.
  • Xiao J, Högger P.
    Stability of polyphenols under the cell culture conditions: avoiding erroneous conclusions.
    J Agric Food Chem 2015; 63: 1547-57.
  • Mülek M, Fekete A, Wiest J, Holzgrabe U, Müller MJ, Högger P.
    Profiling a gut microbiota-generated catechin metabolite’s fate in human blood cells using a metabolomic approach.
    J Pharm Biomed Anal 2015; 114: 71-81.
  • Scherf-Clavel M, Högger P.
    Analysis of metformin, sitagliptin and creatinine in human dried blood spots.
    J Chromatogr B 2015; 997: 218-228.
  • Mülek M, Seefried L, Genest F, Högger P.
    Distribution of constituents and metabolites of maritime pine bark extract (Pycnogenol®) into serum, blood cells and synovial fluid of patients with severe osteoarthritis.
    Nutrients 2017; 9: 443.
  • Jessberger S, Högger P, Genest F, Salter D, Seefried L.
    Cellular pharmacodynamic effects of Pycnogenol® in patients with severe osteoarthritis: a randomized controlled pilot study.
    BMC Complement Altern Med 2017; DOI: 10.1186/s12906-017-2044-1.
Übersichtsartikel und Buchkapitel
  • Högger P, Sadée W, Lameh J.
    The muscarinic acetylcholine receptors.
    In Biomembranes, JAI Press Inc., 1996; Vol. 2B; pp 301-320.
  • Högger P, Rohdewald P.
    Glucocorticoid receptors and fluticasone propionate.
    Rev Contemp Pharmacother 1998; 9: 501-522.
  • Högger P.
    Dose response and therapeutic index of inhaled corticosteroids in asthma.
    Curr Opinion Pulm Med 2003; 9: 1-8.
  • Högger P.
    Pharmakokinetik und Pharmakodynamik von Glucocorticoiden.
    Pharm Unserer Zeit 2003; 32: 296-301.
  • Högger P.
    Current concepts for optimizing the therapeutic index of glucocorticoid receptor ligands for oral and inhalative use: basic considerations and clinical reality.
    Curr Med Chem Anti-Inflamm Anti-Allergy Agents 2003; 2: 395-408.
  • Högger P.
    Explaining pulmonary pharmacokinetics of inhaled corticosteroids: how close to in vivo reality can we get?
    In Respiratory Drug Delivery X, Davies Healthcare International Publishing, 2006; pp 205-217.
  • Högger P.
    French maritime pine bark extract (Pycnogenol®) for metabolic syndrome.
    Agro Food Industry hi-tech 2007; 18: 46-49.
  • Högger P.
    Unterschiede bei inhalativ und nasal angewendeten Glukokortikoiden – Pharmakologische Aspekte und ihr klinischer Bezug.
    Internistische Praxis 2009; 49: 609-622.
  • Högger P.
    Interaktionscheck Klacid®-Viani® – Nebenwirkungen durch Arzneimittelwechselwirkung?
    Pädiatrische Allergologie in Klinik und Praxis 2010; 13: 15-17.
  • Högger P.
    Glucocortikoidhaltige Magistralrezepturen – Rationaler Einsatz in der Dermatologie.
    Pharm Unserer Zeit 2010; 39: 294-299.
  • Högger P.
    Verstärkte Agitiertheit hyperaktiver Kinder mit Asthma bronchiale unter Co-Therapie mit Ritalin® und inhalativen Bronchodilatatoren?
    Pädiatrische Allergologie in Klinik und Praxis 2011; 14: 20-21.
  • Högger P.
    Klinische Pharmakologie systemisch angewandter Glucocorticoide und der Stellenwert des Methylprednisolons.
    In „Festschrift Urbason“; in press
  • Högger P.
    Critical formulation aspects of local corticosteroids.
    Eur J Hosp Pharm 2011; 17: 60-61.
  • Klimek L, Schendzielorz P, Högger P.
    Nasale Glucokortikosteroid-Therapie: Ein Update.
    Allergologie 2011; 34: 307-318.
  • Högger P.
    Stellenwert der b2-Sympathomimetika in der Therapie des Asthma bronchiale.
    Pharm Unserer Zeit 2011; 40: 410-416.
  • Klimek L, Högger P, Pfaar O.
    Wirkmechanismen nasaler Glukokortikosteroide in der Therapie der allergischen Rhinitis.
    Teil 1: Pathophysiologie, molekulare Grundlagen
    HNO 2012; 60: 611-617.
  • von Bernus L, Högger P, Pfaar O, Klimek L.
    Wirkmechanismen nasaler Glukokortikosteroiden in der Therapie der allergischen Rhinitis.
    Teil 2: Praxisorientierte Aspekte in der Anwendung.
    HNO 2012; 60: 700-706.
  • Högger P.
    Nutrition-derived bioactive metabolites produced by gut microbiota and their potential impact on human health.
    NUME 2013; 1: 1.
  • Xiao J, Högger P.
    Metabolism of dietary flavonoids in liver microsomes.
    Curr Drug Metab 2013; 14: 381-91.
  • Xiao J, Högger P.
    Influence of diabetes on the pharmacokinetic behavior of natural polyphenols.
    Curr Drug Metab 2014; 15: 23-29.
  • Högger P.
    Gibt es pharmakologische Bedenken gegen die gleichzeitige Einnahme von Antihistaminika bei Allergien und Antiepileptika?
    Pädiatrische Allergologie in Klinik und Praxis 2014; 17: 15-16.
  • Högger P.
    Optimizing ICS suspensions for nasal use: the influence of solubility, stability, spray volume, dose, log P and receptor binding.
    In Respiratory Drug Delivery, Davies Healthcare International Publishing, 2014; pp 75-87.
  • Xiao J, Högger P.
    Diabetes and dietary polyphenols: current insights and future perspectives.
    Curr Med Chem 2015; 22: 23-38.
  • Högger P.
    Inhalative und intranasale Glucocorticoide.
    Pharmakon 2015; 3: 55-60.
  • Pospiech A, Zilker M, Holzgrabe U, Högger P, Scheiber J.
    Mehr Sicherheit bei der Off-Label-Anwendung in der Pädiatrie.
    Krankenhauspharmazie 2015; im Druck.
Abgeschlossene Dissertationen

Anagnostis Valotis, Ph.D. (2005)
Pharmakokinetische und molekularpharmakodynamische Aspekte inhalativ angewandter Glucocorticoide

Tanja Grimm, Ph.D. (2005)
Antiinflammatorische Wirkungen und Pharmakokinetik eines standardisierten Kiefern­rindenextraktes

Meike Timmermann, Ph.D. (2005)
Zelluläre Regulation und klinische Aspekte des monocyten-/macrophagenspezifischen Proteins CD163

Matthias Freiwald, Ph.D. (2007)
Therapeutisches Zielorgan Lunge: Pharmakokinetische Untersuchungen am humanen Lungenperfusionsmodell

Julia Thern, Ph.D. (2007)
Pharmazeutische Betreuung von Kindern mit Asthma bronchiale in ambulanter Therapie

Samar Afify, Ph.D. (2007)
Drug targeting delivery systems for treatment of Raf-1 induced lung tumors in mice

Angelika Schäfer, Ph.D. (2007)
Effekte von Bestandteilen und Metaboliten eines Rindenextraktes von Pinus maritima (Pycnogenol®) auf pathophysiologische Aspekte des metabolischen Syndroms

Mirjam Gnadt, Ph.D. (2011)
Pharmacokinetic and pharmacodynamic characterization of inhaled β2 – agonists using the isolated human lung perfusion model

Daniel Baumann, Ph.D. (2011)
Charakterisierung der Pharmakokinetik und Pharmakodynamik intranasaler Glucocorticoide anhand von in vitro und ex vivo Modellen

Max Kurlbaum, Ph.D. (2011)
Verteilungsvorgänge und Metabolismus ausgewählter Verbindungen eines standardisierten Kiefernrindenextraktes in menschlichem Blut

Beatrice Trammer, Ph.D. (2011)
Ex-vivo-Modelle zur Charakterisierung der Pharmakokinetik pulmonal applizierter Wirkstoffe: Dialyse- und humanes Lungenperfusionsmodell

Klaus Uhlenhut, Ph.D. (2012)
Effekte eines standardisierten Kiefernrindenextraktes und dessen Metabolit auf NO und NO-Synthasen

Arabe Ahmed, Ph.D. (2014)
Assessing particle deposition in a representative in vitro model of the rat respiratory tract

Frederic Vollmers, Ph.D. (2015)
Charakterisierung der pulmonalen Pharmakokinetik von Salmeterol und Insulin-like Growth Factor-1

Martin Haas, Ph.D. (2016)
Charakterisierung pharmakokinetischer und pharmakodynamischer Aspekte der Anwendung von Glucocorticoiden in der Herzschrittmachertherapie anhand von ex-vivo und in-vitro Modellen

Melanie Mülek, Ph.D. (2016)
Distribution and metabolism of constituents and metabolites of a standardized maritime pine bark extract (Pycnogenol®) in human serum, blood cells and synovial fluid of patients with severe osteoarthritis

Steffen Jeßberger, Ph.D. (2016)
Zelluläre pharmakodynamische Effekte eines standardisierten Kiefernrindenextraktes (Pycnogenol®) bei Patienten mit schwerer Osteoarthritis 

Maike Scherf-Clavel, Ph.D. (2017)
Anwendung der Trockenblutanalytik zur vereinfachten Überwachung der Nierenfunktion und zur Blutspiegelbestimmung von Metformin und Sitagliptin

Kontakt

Institut für Pharmazie und Lebensmittelchemie
Am Hubland
97074 Würzburg

E-Mail

Suche Ansprechpartner

Hubland Süd, Geb. C7